HIV and Cardiovascular Health: Understanding the Connection

For individuals living with Human Immunodeficiency Virus (HIV), maintaining overall health extends beyond managing the virus itself. A growing body of research highlights a significant link between HIV infection and an increased risk of cardiovascular disease (CVD). This article explores the complex relationship between HIV and the heart, outlining the factors involved, current research, and strategies for reducing risk.

The Link Between HIV and Cardiovascular Disease

Historically, CVD was less of a concern for people with HIV due to shorter life expectancies. However, with the advent of Highly Active Antiretroviral Therapy (HAART) and improved management of HIV, individuals are living longer, and chronic conditions like CVD are becoming increasingly prevalent [1]. Persistent inflammation plays a crucial role in this connection, contributing to the development of CVD as an HIV-associated comorbidity [2].

How HIV Impacts the Cardiovascular System

Several factors contribute to the increased CVD risk in people with HIV:

• Inflammation: HIV infection causes ongoing immune activation and inflammation, even with effective antiretroviral therapy. This chronic inflammation damages blood vessels and promotes the development of atherosclerosis (plaque buildup) [3].
• Immune Dysfunction: HIV disrupts the immune system, leading to imbalances that can contribute to cardiovascular problems.
• Antiretroviral Therapy (ART): Even as life-saving, some ART medications have been associated with metabolic changes, such as increased cholesterol and triglycerides, which are risk factors for CVD.
• Shared Risk Factors: People with HIV may have a higher prevalence of traditional CVD risk factors like smoking, hypertension, and diabetes.

Specific Cardiovascular Complications

Individuals with HIV are at increased risk for a range of cardiovascular complications, including:

• Coronary Artery Disease: Narrowing of the arteries that supply blood to the heart.
• Heart Failure: The heart’s inability to pump enough blood to meet the body’s needs.
• Stroke: Disruption of blood flow to the brain.
• Peripheral Artery Disease: Narrowing of the arteries in the limbs.

Research on Monocytes and CVD in HIV

Recent research has focused on the role of monocytes – a type of white blood cell – in the development of CVD in people with HIV. Studies have shown that circulating monocytes in individuals with long-term HIV infection exhibit altered gene expression, potentially serving as viral reservoirs and contributing to inflammation [2]. These changes are amplified in those with both HIV and subclinical CVD. Specifically, non-classical monocytes (NCM) demonstrate extensive gene expression signatures, and the presence of both HIV and CVD leads to a measurable gene transcription signature that can be mitigated by lipid-lowering treatment [2].

Managing Cardiovascular Risk in People with HIV

Proactive management of cardiovascular risk is crucial for individuals living with HIV. Key strategies include:

• Regular Medical Checkups: Routine monitoring of blood pressure, cholesterol levels, and other cardiovascular risk factors.
• Healthy Lifestyle: Adopting a heart-healthy diet, engaging in regular physical activity, and maintaining a healthy weight.
• Smoking Cessation: Quitting smoking is essential for reducing CVD risk.
• Adherence to ART: Consistent adherence to antiretroviral therapy to maintain viral suppression and immune function.
• Lipid Management: If cholesterol levels are elevated, medication may be necessary to lower them.

Allergic Considerations in HIV Patients

HIV infection can also influence allergic diseases. Patients with HIV display an increased prevalence of allergic rhinitis, adverse drug reactions, and noninfectious pulmonary complications [1]. Immune reconstitution with HAART can sometimes provoke immunopathologic conditions, requiring careful evaluation and management of allergic symptoms.

Looking Ahead

As people with HIV continue to live longer, the focus on cardiovascular health will only intensify. Ongoing research is crucial to better understand the complex interplay between HIV, inflammation, and CVD, leading to more effective prevention and treatment strategies. A collaborative approach between HIV specialists and cardiologists is essential to provide comprehensive care for this population.